Tokio Marine Asset Management Co. Ltd. Invests $2.03 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Tokio Marine Asset Management Co. Ltd. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 4,444 shares of the biopharmaceutical company’s stock, valued at approximately $2,026,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $662,837,000. Holocene Advisors LP bought a new stake in Alnylam Pharmaceuticals in the second quarter worth about $194,616,000. Orbis Allan Gray Ltd boosted its stake in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after acquiring an additional 240,534 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Alnylam Pharmaceuticals by 4,085.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 169,700 shares of the biopharmaceutical company’s stock worth $55,337,000 after purchasing an additional 165,645 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company unveiled its new five‑year “Alnylam 2030” strategy focused on scaling operations, TTR leadership, sustainable innovation and disciplined financial execution; release also referenced preliminary Q4 and full‑year 2025 net product results — this provides a clear roadmap for growth and investor targets. Alnylam Launches “Alnylam 2030” Strategy
• Positive Sentiment: Analyst support: Needham raised its price target to $529 and reiterated a Buy rating, signaling continued sell‑side conviction in Alnylam’s multi‑year upside. Alnylam Lays Out 2030 Vision
• Positive Sentiment: Management presented at the J.P. Morgan Healthcare Conference and did media interviews outlining development goals and a path to profitability — these public investor communications should help clarify execution milestones and near‑term catalysts. ALNY Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Alnylam CEO on development goals, profitability (video)
• Neutral Sentiment: Bank of America adjusted its price target down marginally from $530 to $529 but maintained a Buy rating — little practical change to guidance for investors. Benzinga coverage of analyst price target changes
• Neutral Sentiment: Industry/competitive notes: market reports and coverage (atherosclerotic CVD market outlook; AbbVie’s PD‑1/VEGF moves) provide broader context but are not direct company‑specific catalysts. Atherosclerotic Cardiovascular Disease Market report AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
• Negative Sentiment: Short interest rose materially in December to ~5.53M shares (≈4.2% of shares outstanding) with a short‑interest ratio ~2.9 days — elevated short exposure can amplify downward pressure and volatility. (Internal short‑interest reporting)

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. The trade was a 19.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 37,778 shares of company stock worth $17,096,988. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Down 6.9%

ALNY opened at $370.91 on Tuesday. The firm has a market capitalization of $49.00 billion, a P/E ratio of 1,545.46 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a fifty day moving average price of $424.46 and a 200-day moving average price of $421.61. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49.

Analyst Ratings Changes

Several brokerages have weighed in on ALNY. The Goldman Sachs Group increased their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Royal Bank Of Canada boosted their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, September 19th. Leerink Partners cut their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research note on Monday. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $490.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.